Idt Australia Limited · ASX:IDT
Idt Australia — Shareholder Meeting (October 2016)
19 slides from Idt Australia's shareholder meeting presentation, Oct 17, 2016
Slide 1: Good Medicine
For personal use only GOOD MEDICINE Oct16
Slide 2: Investment Proposition
IDT AUSTRALIA LTD (ASX.IDT) INVESTMENT PROPOSITION For personal use only The Business: US FDA approved 23 generic drug portfolio Aggregate Addressable Two in-house products, one FDA approved Market over US$750m Growing contract drug development revenues Growing contract drug manufacturing revenues G
Slide 3: 2015/16 Year on Year Growth
2015/16 YEAR ON YEAR GROWTH For personal use only 18000 Revenue, Full Year ($000’s) 16000 14000 12000 10000 8000 6000 4000 2000 0 FY12 FY13 FY14 FY15 FY16 CAGR 14% www.idtaus.com.au 3
Slide 4: Comparative Results
2015/16 For personal use only COMPARATIVE RESULTS Year on year comparison ($000’s) 20,000 15,000 10,000 5,000 ‐ FY14 FY15 FY16 ‐5,000 ‐10,000 CMAX Sales Boronia Sales Total Sales Revenue Profit 2016 results impacted by investment in Capacity, and generics development www.idtaus.com.au 4
Slide 5: Half Year Results
2015/16 HALF YEAR RESULTS For personal use only Company Performance 1H vs 2H 12,000 10,000 8,000 6,000 4,000 2,000 ‐ 1H FY16 2H FY16 ‐2,000 ‐4,000 ‐6,000 CMAX Sales Boronia Sales Total Sales Revenue Profit IDT results improved in the second half against the long term trend www.idtaus.com.au 5
Slide 6: IDT Generic Portfolio Snapshot
IDT GENERIC PORTFOLIO SNAPSHOT For personal use only • 24 product portfolio with multiple SKUs • Aggregate US addressable markets US$750m+ • Further product in development • Variety of clinical indications • Most are solid oral dose (tablets or capsules) • Good facility fit to IDT Boronia manufactur
Slide 7: Portfolio Progress and Potential
IDT PORTFOLIO PROGRESS and POTENTIAL For personal use only Product Priority Manufacturer US Distributor Addressable Market (US$ millions, 2015) Carbi/Levodopa 1 Wellspring ANI $65 Diflunisal 1 Wellspring ANI $9 Doxazosin 1 IDT ANI $84 Flecainide 1 TBA TBA $39 Leucovorin 1 IDT ANI $2 Mexiletine 1 Wel
Slide 8: Completed Portfolio Milestones as at Oct16
COMPLETED PORTFOLIO MILESTONES as at Oct16 For personal use only Temozolomide Development Manufactured Stability FDA Review Marketing Approval Doxazosin Development Manufactured Stability Leucovorin Development Manufactured Pindolol Development Manufactured Stability Prazosin Development Thiotepa De
Slide 9: Product: Temozolomide
PRODUCT TEMOZOLOMIDE For personal use only • Addressable US market US$200m (Dec15) • Treatment for a variety of malignant brain cancers • ANDA filed Dec2013 • ANDA approved by FDA March 2016 • Mayne Pharma appointed as distributor • IDT manufacture • Likely launch window Q2 FY2016/17 www.idtaus.com.
Slide 10: Product: Doxazosin
PRODUCT DOXAZOSIN For personal use only • Addressable US market US$84m (Dec15) • Treatment for benign prostatic hyperplasia • Development and stability studies complete • Likely Prior Approval Supplement pathway • ANI Pharma appointed as distributor • IDT manufacture • Likely launch window H2 FY2016
Slide 11: Product: Pindolol
PRODUCT PINDOLOL For personal use only • Addressable US market US$10m (Dec15) • Treatment for hypertension • Development complete • Likely CBE30 pathway • ANI Pharma appointed as distributor • Wellspring manufacture • Likely launch window Q2/3 FY2016/17 www.idtaus.com.au 11
Slide 12: Product: Thiotepa
PRODUCT THIOTEPA For personal use only • C. US$12m API product for IDT over the next four years • Addressable global finished good (injectable) market US$80m (estimate) • Treatment for stem cell transplant preparedness and relapsing hormone dependant cancers • Development prototyping complete • ANDA
Slide 13: IDT US Distributor Snapshot
IDT US DISTRIBUTOR SNAPSHOT (15Jun16) For personal use only ANI Pharma (NASDAQ:ANIP) Mayne Pharma (ASX. • Market cap. US$630m • Market cap. US$1.3b • Located Minnesota, USA • Located Salisbury, Australia • US wide distribution and North Carolina, USA capability • US wide distribution • Focus on spec
Slide 14: Product: Contract Manufacturing
PRODUCT CONTRACT MANUFACTURING For personal use only • Revenue growth continues, with reactivation of most of the Melbourne site • Some headcount expansion has been needed to service this reactivation • Higher than anticipated CAPEX: repairs, facility remodelling and capacity expansion • Reliable ba
Slide 15: Plant and Site Upgrades and Expansions
PLANT AND SITE UPGRADES AND EXPANSIONS For personal use only • Building of new cytotoxic capsuling and packing lines – Expanded capacity for temozolomide – Better segregation of potent and non‐potent molecules • New, larger tableter and blender: – Tripling of tableting capacity – Reduction in doxazo
Slide 16: Product: Clinical Services
PRODUCT CLINICAL SERVICES For personal use only • Oldest, largest and most experienced clinical unit in Australia • New, state‐of‐the‐art facility recently opened in Adelaide • Consistent double digit year on year growth • Reliable, predictable profits and free cash generation • Strong forward work
Slide 17: Target: 2016 Milestones Achieved
TARGET 2016 MILESTONES ACHIEVED For personal use only INCREASED ORGANIC SALES TOWARDS PROFITABILITY ✔ CONTINUE TO PROGRESS TEMOZOLOMIDE THROUGH FDA ✔ MOVEMENT OF AN ADDITIONAL INTERNAL PRODUCT TOWARDS MARKET ✔ PROGRESS WITH RE-COMMERCIALISATION OF US GENERIC PORTFOLIO ✔ MOVE FROM SERVICE PROVIDER, T
Slide 18: Financially Positioned to Deliver
FINANCIALLY POSITIONED TO DELIVER For personal use only FINANCIALS (ASX: IDT) CAPITAL STRUCTURE $m Total 1st Half 2nd Half Total Year SHARES ON ISSUE 248.2M 2015 2016 2016 2016 on Year % Revenue 15.7 6.4 10.5 16.9 7.6% UNLISTED OPTIONS 500,000 Operating Loss 3.0 3.5 0.5 4.0 33.9% After Tax STOCK PRI
Slide 19: Summary: 2016/17 Year Outlook
SUMMARY 2016/17 YEAR OUTLOOK For personal use only • Modest growth of base business revenues expected to continue • Cost containment while supporting growth and new business remains a key focus • First proprietary generic product launches expected this year, with steady rollout to follow • More gene